Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset (ID:20270)
Download: Excel (XLSX), Comma-separated (CSV)
Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | GR50 lower quartile | GR50 median | GR50 upper quartile | GRmax lower quartile | GRmax median | GRmax upper quartile | GRinf lower quartile | GRinf median | GRinf upper quartile | Hill Coefficient lower quartile | Hill Coefficient median | Hill Coefficient upper quartile | GR_AOC lower quartile | GR_AOC median | GR_AOC upper quartile | GEC50 lower quartile | GEC50 median | GEC50 upper quartile |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 36.5873 | 68.4588 | 100.0000 | -0.7737 | -0.2023 | 0.2203 | -0.7439 | -0.3900 | 0.2345 | 0.6570 | 1.9429 | 3.4993 | 0.1339 | 0.2188 | 0.2978 | 54.8881 | 71.4700 | 100.0000 | |
GSK1838705A | IGF1R | RTK | 4.0665 | 10.9435 | 23.1329 | -0.6969 | -0.3849 | -0.1067 | -0.7773 | -0.4275 | -0.2150 | 1.5275 | 2.6721 | 3.2208 | 0.2264 | 0.2964 | 0.4149 | 2.6121 | 7.6760 | 17.5013 | |
Epirubicin | TOP2 | TOP | 0.2120 | 0.3019 | 0.4930 | -0.9915 | -0.9463 | -0.8152 | -0.8492 | -0.7437 | -0.6556 | 0.9325 | 1.4047 | 2.1457 | 0.6134 | 0.7438 | 0.8467 | 0.3985 | 0.6015 | 1.3650 | |
Doxorubicin | TOP2 | TOP | 0.1488 | 0.2099 | 0.7023 | -0.9456 | -0.8552 | -0.5483 | -0.8723 | -0.7083 | -0.3772 | 1.0561 | 1.4782 | 2.5260 | 0.5209 | 0.6697 | 0.8073 | 0.2444 | 0.4713 | 1.2126 | |
Topotecan | TOP1 | TOP | 0.0324 | 0.1223 | 0.4672 | -0.7615 | -0.5906 | -0.2740 | -0.8265 | -0.6901 | -0.4582 | 0.5573 | 0.7931 | 1.1373 | 0.5801 | 0.7088 | 0.8375 | 0.0774 | 0.7078 | 1.2170 | |
CPT-11 | TOP1 | TOP | 3.1544 | 10.7270 | 20.8553 | -0.5980 | -0.2192 | 0.1666 | -0.9688 | -0.6234 | -0.1292 | 0.8799 | 1.3528 | 1.8883 | 0.1220 | 0.2195 | 0.2928 | 7.3583 | 23.7091 | 36.8667 | |
ICRF-193 | TOP2 | TOP | 8.5852 | 100.0000 | 100.0000 | 0.3561 | 0.5910 | 0.6710 | 0.2252 | 0.4446 | 0.6698 | 0.1440 | 0.6745 | 1.5658 | 0.1152 | 0.1622 | 0.2393 | 0.3708 | 3.7956 | 100.0000 | |
Etoposide | TOP2 | TOP | 1.1610 | 2.9708 | 7.6285 | -0.6938 | -0.4841 | -0.2079 | -0.7406 | -0.5842 | -0.4690 | 0.5531 | 0.8108 | 1.2247 | 0.3770 | 0.4769 | 0.5711 | 4.4274 | 7.6731 | 19.6965 | |
Vinorelbine | TUBB | TUBB | 0.0079 | 0.0130 | 0.0470 | -0.9358 | -0.8653 | -0.6758 | -1.0000 | -0.5683 | -0.3360 | 0.3815 | 2.2644 | 3.6055 | 0.6197 | 0.8320 | 1.0409 | 0.0132 | 0.0302 | 0.9743 | |
Taxol | TUBB | TUBB | 0.0078 | 0.0104 | 0.0155 | -0.5505 | -0.2204 | 0.0319 | -0.5168 | -0.1393 | 0.1113 | 1.6357 | 2.0915 | 3.1238 | 0.5399 | 0.6855 | 0.9358 | 0.0096 | 0.0111 | 0.0153 | |
Ixabepilone | TUBB | TUBB | 0.0045 | 0.0114 | 0.0487 | -0.9765 | -0.9460 | -0.8485 | -0.9892 | -0.7196 | -0.5742 | 0.3937 | 0.7623 | 1.6684 | 0.6842 | 0.8505 | 0.9658 | 0.0102 | 0.0892 | 0.7025 | |
Docetaxel | TUBB | TUBB | 0.0022 | 0.0051 | 0.0098 | -0.3944 | -0.0464 | 0.1697 | -0.4257 | -0.0477 | 0.1373 | 1.4024 | 1.6746 | 2.3040 | 0.4979 | 0.6215 | 0.8198 | 0.0027 | 0.0049 | 0.0080 | |
5-DFUR | TYMS | TYMS | 68.5295 | 100.0000 | 100.0000 | -0.1871 | -0.0208 | 0.0399 | -0.5625 | -0.3158 | -0.1425 | 0.3943 | 0.5084 | 0.6195 | 0.2584 | 0.3100 | 0.3856 | 100.0000 | 100.0000 | 100.0000 | |
5-FU | TYMS | TYMS | 43.5628 | 98.8715 | 100.0000 | -0.6126 | -0.4736 | -0.0711 | -0.8532 | -0.6532 | -0.1200 | 0.5225 | 0.5967 | 0.7832 | 0.3295 | 0.4853 | 0.6100 | 100.0000 | 100.0000 | 100.0000 | |
Pemetrexed | TYMS/DHFR/GARFT | TYMS | 70.1583 | 100.0000 | 100.0000 | 0.5012 | 0.6411 | 0.8577 | 0.5144 | 0.6941 | 0.8649 | 0.0000 | 0.7943 | 1.8547 | 0.0614 | 0.1870 | 0.3357 | 0.9463 | 34.1832 | 100.0000 |